IL-33 Inhibitor

Astegolimab (MSTT 1041A; RG 6149) is a human IgG2 monoclonal antibody. Astegolimab blocks IL-33 signaling by targeting the IL-33 receptor ST2. Astegolimab reduces p53 expression, mitigates IL33-upregulated SASP factors such as IL1α, IL6 and MCP1. Astegolimab mitigates IL33-increased p-p65/p65 ratio. Astegolimab blocks CM-induced neutrophil extracellular trap (NET) formation. Astegolimab is used in chronic obstructive pulmonary disease (COPD) and myocardial research.

Melrilimab (GSK 3772847; CNTO-7160) is a humanized IgG2σ monoclonal antibody that targets the IL-33 receptor ST2 and blocks the IL-33/ST2 signaling pathway by binding to the ST2 protein. Melrilimab is applicable to research related to asthma and atopic dermatitis.

iST2-1 is an Stimulation-2 (ST2) inhibitor with an IC₅₀ value of 46.65 μM, blocks interaction between ST2 and IL-33, inhibits downstream signaling. iST2-1 functions as an immunomodulator, reduces proliferation of CD4⁺ and CD8⁺ T cells, increases regulatory T cell populations, reduces IFN-γ⁺CD4⁺ T cell populations, increases Foxp3⁺CD4⁺ regulatory T cell populations in the gastrointestinal tract. iST2-1 reduces plasma soluble ST2 and IFN-γ levels, reduces graft-versus-host disease scores, improves survival in graft-versus-host disease animal models, preserves graft-versus-tumor effect. iST2-1 can be used for the research of graft-versus-host disease.

TQC2938 is a humanized IgG2 monoclonal antibody inhibitor targeting Stimulation-2 (ST2). TQC2938 inhibits the ST2/IL-33 signaling pathway, reduces the level of downstream Th2 cytokines (such as IL-4, IL-5, and IL-13) and eosinophils as well as other inflammatory cells. TQC2938 can be used for inflammatory diseases like asthma research.

PF-06817024 is a high affinity, humanized antibody that binds IL-33. PF-06817024 binds to IL-33, prevents IL-33 from binding to receptor ST2, and inhibits downstream type 2 inflammatory responses. PF-06817024 can be used for the research of allergic diseases.